Nuclera, the biotechnology company accelerating protein expression and optimisation through its benchtop eProtein Discovery System, has announced a collaboration with Cytiva.
Cinclus Pharma Holding has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe.
Kaida BioPharma, an earlystage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, has entered into a manufacturing agreement with Northway Biotech, for the manufacturing of KAD101.
Mirai Bio (Mirai) has announced a strategic collaboration with Thermo Fisher Scientific to benefit the life sciences and genetic medicines marketplace.
GC Biopharma, a South Korean biopharmaceutical company, has partnered with global tech leader Körber to implement a large-scale Manufacturing Execution System (MES) project across multiple sites.
Capula, a specialist in advanced operational technology and industrial digitalisation, has announced a partnership with Dimension Software, a New Zealand-headquartered global provider of operational intelligence solutions.
ProBioGen has announced an agreement with Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars.
NewBiologix has announced it has granted a non-exclusive technology license to ReciBioPharm to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.
Astraveus, the benchtop cell factory company, has announced that it has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen).
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva to provide customers with an integrated offering for optimised biologics production.
Ferrer, a pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement.
